沙库巴曲缬沙坦在心力衰竭治疗中的研究进展

Treatment of Heart Failure by Sacubitril/Valsartan

沙库巴曲缬沙坦由抑制脑啡肽酶的沙库巴曲和抑制肾素-血管紧张素-醛固酮系统的缬沙坦组成,是目前治疗射血分数降低的慢性心力衰竭患者的新型药物。与依那普利相比,沙库巴曲缬沙坦不仅可进一步降低心力衰竭住院率、心血管病死亡率和全因死亡风险而且有更好的安全性和耐受性。沙库巴曲缬沙坦获得了欧美指南的一致推荐,值得在中国推广应用,现就沙库巴曲缬沙坦的机制及目前应用的现状做一综述。

Sacubitril/valsartan is composed of sacubitril inhibiting enkephalin enzyme and valsartan inhibiting renin-angiotensin-aldosterone system,which is a new drug for the treatment of chronic heart failure patients with reduced ejection fraction.Compared with enalapril,sacubitril/valsartan not only reduces hospitalization rate of heart failure,cardiovascular mortality and all-cause mortality,but also has better safety and tolerance.At present,the sacubitril/valsartan obtained the consistent recommendation of European and American guides,which is worth popularizing and applying in China.This paper reviews the mechanism and current application of sacubitril/valsartan.